Full-Time

Manager Customer Service 1

Posted on 5/16/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Customer Experience & Support (1)
Required Skills
UiPath
SAP Products
Salesforce
Data Analysis
Requirements
  • 6–8 years of experience in customer service, order-to-cash, supply chain, or customer experience operations within a B2B and/or B2C environment
  • 2–4 years of people management experience, preferably in a global or shared services model
  • Familiarity with ERP and CRM platforms such as SAP and Salesforce required
  • Data-driven approach with experience using performance metrics and analytics
  • Bachelor’s degree required; Master’s degree preferred
Responsibilities
  • Lead and manage daily operations of assigned customer service teams, ensuring delivery of best-in-class customer experience
  • Drive improvements in customer satisfaction, response times, resolution quality, and service reliability
  • Act as an escalation point for complex customer issues, ensuring timely resolution and root cause mitigation
  • Ensure consistent execution of global GCX-OTC service models, SOPs, SLAs, and KPIs
  • Oversee OTC activities within scope, including order management, customer inquiries, product and distribution complaints, and dispute resolution
  • Ensure adherence to global OTC processes, controls, and performance standards
  • Partner closely with Finance, Supply Chain, Quality, Compliance, Commercial, Technology/IS, and outsource partners to resolve issues and optimize workflows
  • Support alignment and harmonization of service processes across commercial and digital customer channels
  • Monitor team performance using dashboards, reports, and key metrics to identify trends and improvement opportunities
  • Leverage platforms such as SAP, Salesforce Service Cloud/eCommerce, Celonis, and UiPath to enhance service efficiency and accuracy
  • Ensure accurate documentation and system usage across customer interactions and transactions
  • Contribute to analytics initiatives that illuminate customer experience pain points and operational gaps
  • Lead and support continuous improvement initiatives focused on process optimization, automation, and service quality
  • Apply a “perfection through iteration” mindset by testing, learning, and refining solutions
  • Support transformation initiatives and change management efforts within GCX-OTC operations
  • Stay current on industry trends, customer service best practices, and digital capabilities
  • Lead, coach, and develop team leads and customer service agents, building strong engagement and performance
  • Set clear goals, expectations, and accountability aligned with business objectives
  • Promote and model Amgen Values and GCX-OTC culture, fostering a positive and inclusive employee experience
  • Manage performance, feedback, and development planning in a fast-paced, global environment
  • Support workforce planning, onboarding, and capability building for current and future needs
Desired Qualifications
  • 2–4 years of people management experience, preferably in a global or shared services model
  • Experience leading contact center teams; exposure to outsourced environments preferred
  • Experience supporting process improvement or transformation initiatives (could be considered desirable but listed as requirement here)
  • Experience working with U.S.-based companies or global stakeholders preferred
  • Spanish and/or French language proficiency is a plus
  • Master’s degree

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • MariTide’s once-monthly dosing could improve adherence in obesity if Phase 3 succeeds.
  • Repatha’s 34% Q1 2026 sales growth shows strong cardiovascular momentum.
  • China approval for tarlatamab opens a meaningful ex-U.S. growth opportunity.

What critics are saying

  • Prolia’s 34% Q1 2026 sales decline shows biosimilar and competitive erosion is already happening.
  • Tavneos faces FDA liver-injury scrutiny, risking label restrictions, slower uptake, or withdrawal.
  • TrumpRx discounts on Repatha, Aimovig, and Amjevita will compress net pricing immediately.

What makes Amgen unique

  • Amgen pairs deep biologics expertise with targeted small molecules and bispecific antibodies.
  • The January 2026 Dark Blue acquisition adds first-in-class MLLT1/3 degraders for AML.
  • Human genetic validation anchors Amgen’s pipeline selection and de-risks development.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Amgen who can refer or advise you

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.